JAX CO >>CORLEY PEEL: ACCORDING TO THE AMERICAN HEART ASSOCIATION MORE
THAN 30 MILLION AMERICANS ARE
DEALING WITH VARIOUS FORMS OF
HEART DISEASE. SOME ALSO FACE
ANOTHER HEALTH CHALLENGE AT THE
VERY SAME TIME. A DIAGNOSIS
OF CANCER. MANY OF THESE
PATIENTS BENEFIT FROM US
MEDICAL SPECIALTY CALLED
CARDIO ONCOLOGY AND JOINING US
NOW IS CARDIOLOGIST AND ON
COLLEGES FROM MAYO CLINIC.
DOCTOR JORDAN, RAY THANKS SO
MUCH FOR BEING WITH US
THIS MORNING.
>> ABSOLUTELY THANKS FOR HAVING
ME THE FIRST QUESTION I HAVE
FOR YOU
HOW ARE THESE 2 AILMENTS
RELATED WHY DID THEY GO
TOGETHER.
>> THAT’S A VERY GOOD
WE KNOW THAT THERE ARE
CERTAIN MALIGNANCIES LIKE
BREAST CANCER THAT ARE ACTUALLY
ASSOCIATED WITH CARDIOVASCULAR
SOME OF THE COMMON RISK FACTORS
THAT LED
TO BOOST. OCCUR IN PATIENTS AND
WE TRADITIONALLY SEE A LOT OF
CARDIOVASCULAR DISEASE AND SOME
OF THOSE BELIEVE IN SEAS
LIKEWISE SOME OF THE CANCER
THERAPIES THAT WE GIVE TO
PATIENTS CAN HAVE SOME
TOXICITIES TO
THE HEART AND WE THAT WE’RE
STARTING TO RECOGNIZE THAT EVEN
MORE NOW AND PROVIDING SOME
PROACTIVE STRATEGIES TO HELP
PATIENTS GO THROUGH BOTH.
>> SO I’M SURE YOU’RE TALKING
ABOUT CHEMO HERE IN
THE CONNECTION TO HEART
PROBLEMS WHEN SOMEONE GOES
THROUGH CHEMO. WHAT KINDS OF
THINGS CAN YOU DOWE DO TO HELP
PREVENT PROBLEMS.
>> SO THE BIG THING IS
PREVENTION IN RECOGNITION OF
SOME OF THE CONDITIONS THAT CAN
WE KNOW THAT
TRADITIONAL CHEMOTHERAPY IS FOR
PATIENTS, WE’RE EXPERIENCING
BREAST CANCER LYMPHOMA AS SOME
OF US ARE COMAS
CAN BE VERY TOXIC TO THE HEART
AND CAN LEAD TO HEART WEAKENING
AND THEN SOME OF THE NEWER
MEDICATIONS STRATEGIES THAT WE
HAVE ARE ACTUALLY
IMMUNOTHERAPIES WHERE WE’RE
TURNING THE IMMUNE SYSTEM ON
THE FIGHT CANCER.
AND UNFORTUNATELY SOMETIMES
THAT CAN HAVE ADVERSE EFFECTS
ON THE HEART MUSCLE ITSELF.
SO PRESCRIBING AND MONITORING
PROGRAM RECOGNIZING SOME OF THE
RISK FACTORS FOR PATIENTS AND A
BIG PART OF MY JOB IS ACTUALLY
EDUCATION FOR THE PATIENTS
TALKING ABOUT THEIR TRADITIONAL
CARDIOVASCULAR RISKS
AND TRYING TO MODIFY THOSE
BEFORE THERAPY AND PRESCRIBING
SOME TYPE OF MONITORING PROGRAM
DURING THERAPY. >>CORLEY PEEL: SO IF YOU’RE A CANCER PATIENT WATCHING RIGHT
NOW OR SOMEONE YOU LOVE IS ARE
THERE CERTAIN QUESTIONS THAT
THEY SHOULD BE ASKING THEIR
ONCOLOGIST.
>> I THINK SO I THINK IT’S
IMPORTANT FOR PATIENTS,
WE’RE EXPERIENCING CANCER
THERAPIES TO MAKE SURE THAT
THEY’RE ON COLLEGES TO TALK
ABOUT THE CARDIOVASCULAR RISKS
ASSOCIATED WITH
THEIR THERAPIES. WHEN IT COMES
TO RADIATION THERAPIES, IT’S
IMPORTANT TO DISCUSS WITH THEIR
RADIATION ONCOLOGIST THE AMOUNT
OF RADIATION THAT THEY EXPECT
THE HEART TO SEE
AND THE STRUCTURES OF THE HEART
THAT MAYBE IN THE WAY OF
THE RADIATION. BECAUSE THOSE
ARE IMPORTANT THINGS TO FOLLOW
UP ESPECIALLY WITH RADIATION
WHERE IF THE HEART’S EASE
RADIATION, A LOT OF THE EFFECTS
OF RADIATION HEART DISEASE CAN
BE DELAYED UP TO 10 OR 15 YEARS
BEFORE WE NOTICE OR RECOGNIZE
THEM.
>>JENNIFER READY: A LONG-TERM
SURVIVOR OF CANCER ARE THERE
ANY RISKS THERE.
>> YEAH THERE ARE SOME RISKS,
BUT THERE ARE A LOT SMALLER
THAN PATIENTS TO ARE
EXPERIENCING THE CHEMOTHERAPY
IN THAT AT THAT MOMENT
IN TIME. MORE IMPORTANTLY I AND
ANOTHER HALF OF MY JOB
IS SEEN CANCER SURVIVORS
BECAUSE WE’RE GETTING SO MUCH
BETTER AT TREATING CANCER, THE
LONG-TERM OUTCOMES IN CANCER SO
MUCH HIGHER THAT NOT FOCUSING
ARE
TRADITIONAL CARDIOVASCULAR
SOMETIMES GETS OVERSHADOWED.
SO WE’RE SEEING FOR INSTANCE,
WOMEN WITH BREAST CANCER HAVE
EXCEPTIONAL SURVIVAL RATES.
HAVING PRETTY BASKET THAN US
BECAUSE WE FAILED TO RECOGNIZE
THEY HAD CARDIOVASCULAR DISEASE
BEFORE AND SO I VERY MUCH TAKE
SERIOUSLY THAT ASPECT OF THINGS
IT’S VERY UNFORTUNATE FOR
US 10 HAVE PATIENTS GO THROUGH
CANCER THERAPY SURVIVE THEIR
CANCER AND THEN END UP WITH A
CARDIOVASCULAR EVENT LATER ON
IN LIFE.
>> IT’S A RELATIVELY NEW
SPECIALTY CARDIO ONCOLOGY.
>> YEAH, I THINK SO
IT’S IT’S THERE HAVE BEEN A FEW
CARDIO ONCOLOGIST AS WE CALL
THROUGHOUT THE COUNTRY FOR
MAYBE ABOUT 15 YEARS, BUT NOW
WE’RE STARTING TO HAVE AN
INFRASTRUCTURE IN PLACE FOR
SPECIALIZED TRAINING. THERE ARE
DOCUMENTS NOW THAT WE’VE
WRITTEN KIND OF DESCRIBING WHAT
CONSTITUTES AN APPROPRIATE
TRAINING LEVEL 4
PROVIDERS TO WANT TO CONSIDER
THEMSELVES IN THIS AREA OF
SPECIALTY. SO REALLY THE LAST 5
YEARS IT’S GROWN
AND THEN THE LAST 2 TO 3 YEARS
WE’VE SEEN A BIG SPIKE IN
EDUCATION, A BIG SPIKE IN
MOTIVATION FROM THE ONCOLOGY
WORLD TO SUPPORT THESE TYPES OF
CLINICS.
>> FASCINATING FIELD OF STUDY